ArcticZymes Technologies ASA (DE:B4V) has released an update.
ArcticZymes Technologies ASA reported a decrease in Q2 revenue to NOK 27.5 million in 2024 from NOK 28.2 million the previous year, with a positive EBITDA of NOK 2.6 million, although lower than the NOK 6.8 million in Q2 2023. The company is on track with its development projects, planning to launch two new GMP grade nucleases and an ELISA kit in the next 12 months, and is actively pursuing distribution partnerships expected to drive growth in 2025.
For further insights into DE:B4V stock, check out TipRanks’ Stock Analysis page.
